\-\ Texto\\:\\ \ \(0\)\
\-\ thyroglobulin\\ 18\\ ng\\/ml\\.\\ \\(\\ should\\ be\\ undetectable\\ \\)\ \(0\)\
\-\ total\\ or\\ near\\ total\\ thyroidectomy\\ followed\\ by\\ i\\-131\\ treatment\\ and\\ thyroid\\ hormone\\ suppression\\ with\\ continued\\ monitoring\\ of\\ thyroglobulin\\ levels\\ and\\ i\\-131\\ or\\ i\\-123\\ scans\\ usually\\ yearly\\.\\ adjunctive\\ anatomic\\ imaging\\ with\\ ultrasound\\,\\ ct\\,\\ pet\\ or\\ mri\\ scans\\ as\\ indicated\\ on\\ an\\ individual\\ basis\\.\ \(0\)\
\-\ fdg\\ pet\\ scan\\:\\ focus\\ of\\ moderately\\ intense\\ radiotracer\\ accumulation\\ in\\ r\\ supraclavicular\\ region\\.\\ increased\\ uptake\\ in\\ thymus\\.\ \(0\)\
\-\ suspected\\ metastasis\\ of\\ papillary\\ thyroid\\ cancer\ \(0\)\
\-\ metastatic\\ lesion\\,\\ reactive\\ lad\\,\\ granulomatous\\ disease\\,\\ \\ lymphoma\\,\\ retention\\ of\\ fdg\\ in\\ mediport\\.\ \(0\)\
\-\ 25\\ yo\\ female\\ patient\\ with\\ papillary\\ thyroid\\ cancer\\ s\\/p\\ thyroidectomy\\ and\\ i\\-131\\ treatment\\ with\\ recent\\ \\â\\€\\œclean\\â\\€\\\\ neck\\/chest\\ mri\\ but\\ persistently\\ high\\ thyroglobulin\\ levels\\ on\\ followup\\.\ \(0\)\
\-\ papillary\\ thyroid\\ cancer\\ is\\ the\\ most\\ common\\ type\\ of\\ thyroid\\ cancer\\ \\(70\\-90\\%\\ of\\ thyroid\\ malignancies\\)\\.\\ \\ most\\ \\(\\>80\\%\\)\\ are\\ detectedin\\ stage\\ i\\ or\\ ii\\ with\\ survival\\ curves\\ that\\ are\\ similar\\ to\\ normal\\ survival\\ curves\\.\\ \\ treatment\\ usually\\ involves\\ thyroidectomy\\ followed\\ by\\ i\\-131\\ ablation\\.\\ \\ then\\ t4\\ suppression\\ with\\ follow\\ up\\ i\\-131\\ scans\\ and\\/or\\ mri\\ scans\\.\\ \\ patient\\â\\€\\™s\\ thyroglobulin\\ levels\\ are\\ also\\ followed\\ with\\ a\\ persistently\\ high\\ level\\ \\(5\\-10\\ ng\\/ml\\)\\ suggestive\\ of\\ residual\\ thyroid\\ tissue\\/metastasis\\ requiring\\ further\\ workup\\.\\ \\ pet\\ scan\\ showing\\ a\\ lesion\\ with\\ an\\ suv\\ of\\ 3\\.5\\,\\ as\\ in\\ this\\ case\\,\\ is\\ highly\\ suggestive\\ of\\ a\\ metastatic\\ lesion\\,\\ especially\\ in\\ patient\\ with\\ persistently\\ high\\ thyroglobulin\\ levels\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroglobulin\\:\\ 0\\.13580800165900528\ \(0\)\
\-\ i\\-131\\:\\ 0\\.1194586021385148\ \(0\)\
\-\ thyroid\\:\\ 0\\.09885559320352005\ \(0\)\
\-\ persistently\\:\\ 0\\.08310010009973207\ \(0\)\
\-\ thyroidectomy\\:\\ 0\\.07040063891628033\ \(0\)\
\-\ scans\\:\\ 0\\.06418123414540355\ \(0\)\
\-\ curves\\:\\ 0\\.058113552512358044\ \(0\)\
\-\ levels\\:\\ 0\\.0568911515043865\ \(0\)\
\-\ pet\\:\\ 0\\.05425143246387299\ \(0\)\
\-\ papillary\\:\\ 0\\.05247800334058417\ \(0\)\
\-\ suppression\\:\\ 0\\.046933759277520214\ \(0\)\
\-\ ng\\/ml\\:\\ 0\\.045806646839010874\ \(0\)\
\-\ cancer\\:\\ 0\\.04530911716717363\ \(0\)\
\-\ fdg\\:\\ 0\\.044817918435040446\ \(0\)\
\-\ survival\\:\\ 0\\.03694687031749386\ \(0\)\
\-\ detectedin\\:\\ 0\\.03554644525792943\ \(0\)\
\-\ tissue\\/metastasis\\:\\ 0\\.03554644525792943\ \(0\)\
\-\ followed\\:\\ 0\\.03465575650861417\ \(0\)\
\-\ neck\\/chest\\:\\ 0\\.03275149694921997\ \(0\)\
\-\ undetectable\\:\\ 0\\.029956548640510512\ \(0\)\
\-\ 70\\-90\\:\\ 0\\.029956548640510512\ \(0\)\
\-\ total\\:\\ 0\\.029675161184808355\ \(0\)\
\-\ suggestive\\:\\ 0\\.029441390726153097\ \(0\)\
\-\ high\\:\\ 0\\.02828886364205825\ \(0\)\
\-\ adjunctive\\:\\ 0\\.027700033366577358\ \(0\)\
\-\ mediport\\:\\ 0\\.02668666873641241\ \(0\)\
\-\ thymus\\:\\ 0\\.026261827947469566\ \(0\)\
\-\ i\\-123\\:\\ 0\\.024626887995420513\ \(0\)\
\-\ clean\\:\\ 0\\.024626887995420513\ \(0\)\
\-\ mri\\:\\ 0\\.023749304696547822\ \(0\)\
\-\ 5\\-10\\:\\ 0\\.02367370743870991\ \(0\)\
\-\ suv\\:\\ 0\\.02367370743870991\ \(0\)\
\-\ lad\\:\\ 0\\.023466879638760107\ \(0\)\
\-\ yearly\\:\\ 0\\.02327014510581885\ \(0\)\
\-\ retention\\:\\ 0\\.023082564397613636\ \(0\)\
\-\ individual\\:\\ 0\\.021968639491854933\ \(0\)\
\-\ malignancies\\:\\ 0\\.021968639491854933\ \(0\)\
\-\ ablation\\:\\ 0\\.02157170371438214\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.021210364364826952\ \(0\)\
\-\ lesion\\:\\ 0\\.02105510354032808\ \(0\)\
\-\ usually\\:\\ 0\\.020926840756989994\ \(0\)\
\-\ treatment\\:\\ 0\\.02092278580162363\ \(0\)\
\-\ basis\\:\\ 0\\.02067193133005065\ \(0\)\
\-\ t4\\:\\ 0\\.020196999734662012\ \(0\)\
\-\ 3\\.5\\:\\ 0\\.02010837511079598\ \(0\)\
\-\ moderately\\:\\ 0\\.019692309642105534\ \(0\)\
\-\ hormone\\:\\ 0\\.019537203671025714\ \(0\)\
\-\ scan\\:\\ 0\\.01929251177768531\ \(0\)\
\-\ monitoring\\:\\ 0\\.019036991378001605\ \(0\)\
\-\ requiring\\:\\ 0\\.019036991378001605\ \(0\)\
\-\ accumulation\\:\\ 0\\.018358219947278962\ \(0\)\
\-\ intense\\:\\ 0\\.018246205575879464\ \(0\)\
\-\ workup\\:\\ 0\\.017728539581330242\ \(0\)\
\-\ anatomic\\:\\ 0\\.017402051425952553\ \(0\)\
\-\ metastatic\\:\\ 0\\.01734765648077492\ \(0\)\
\-\ residual\\:\\ 0\\.01710003002202869\ \(0\)\
\-\ granulomatous\\:\\ 0\\.016629719926360302\ \(0\)\
\-\ highly\\:\\ 0\\.01659289539586323\ \(0\)\
\-\ followup\\:\\ 0\\.016448870869241947\ \(0\)\
\-\ reactive\\:\\ 0\\.01630981370766465\ \(0\)\
\-\ 80\\:\\ 0\\.01620858015471676\ \(0\)\
\-\ or\\:\\ 0\\.01615359272522109\ \(0\)\
\-\ radiotracer\\:\\ 0\\.016077438252678215\ \(0\)\
\-\ \\%\\:\\ 0\\.016075169623758125\ \(0\)\
\-\ involves\\:\\ 0\\.016013432812531883\ \(0\)\
\-\ most\\:\\ 0\\.01590996082038771\ \(0\)\
\-\ showing\\:\\ 0\\.015857727828145676\ \(0\)\
\-\ r\\:\\ 0\\.015649372946918573\ \(0\)\
\-\ focus\\:\\ 0\\.01547897049010453\ \(0\)\
\-\ 18\\:\\ 0\\.014957955443814184\ \(0\)\
\-\ near\\:\\ 0\\.01490937343366832\ \(0\)\
\-\ indicated\\:\\ 0\\.01490937343366832\ \(0\)\
\-\ ii\\:\\ 0\\.014861369794529938\ \(0\)\
\-\ continued\\:\\ 0\\.014837580592404177\ \(0\)\
\-\ suspected\\:\\ 0\\.014837580592404177\ \(0\)\
\-\ stage\\:\\ 0\\.014697719471485267\ \(0\)\
\-\ and\\/or\\:\\ 0\\.014562547326168155\ \(0\)\
\-\ s\\/p\\:\\ 0\\.014453265351257707\ \(0\)\
\-\ i\\:\\ 0\\.014243204416243991\ \(0\)\
\-\ especially\\:\\ 0\\.014182262328300247\ \(0\)\
\-\ are\\:\\ 0\\.014091216199954858\ \(0\)\
\-\ 25\\:\\ 0\\.013928331686520455\ \(0\)\
\-\ uptake\\:\\ 0\\.013689449293121823\ \(0\)\
\-\ similar\\:\\ 0\\.013514865398955194\ \(0\)\
\-\ metastasis\\:\\ 0\\.012898174702822285\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.012868955313625644\ \(0\)\
\-\ \\â\\€\\\\:\\ 0\\.012796819971888647\ \(0\)\
\-\ then\\:\\ 0\\.01226196321944391\ \(0\)\
\-\ \\(\\:\\ 0\\.011650995584578395\ \(0\)\
\-\ type\\:\\ 0\\.01161542027559238\ \(0\)\
\-\ recent\\:\\ 0\\.011583544551773375\ \(0\)\
\-\ \\)\\:\\ 0\\.011508672453440404\ \(0\)\
\-\ by\\:\\ 0\\.01147476534874899\ \(0\)\
\-\ \\>\\:\\ 0\\.011448256107534534\ \(0\)\
\-\ should\\:\\ 0\\.010984711862454838\ \(0\)\
\-\ further\\:\\ 0\\.010957436055646202\ \(0\)\
\-\ follow\\:\\ 0\\.010948384967525943\ \(0\)\
\-\ as\\:\\ 0\\.010424012144307482\ \(0\)\
\-\ yo\\:\\ 0\\.010368352916543394\ \(0\)\
\-\ patient\\:\\ 0\\.010361999164311145\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.010298494917925225\ \(0\)\
\-\ ultrasound\\:\\ 0\\.010222268487928642\ \(0\)\
\-\ level\\:\\ 0\\.009931004143737628\ \(0\)\
\-\ s\\:\\ 0\\.009882127689978173\ \(0\)\
\-\ lymphoma\\:\\ 0\\.009847575138667282\ \(0\)\
\-\ \\,\\:\\ 0\\.009824155603449946\ \(0\)\
\-\ region\\:\\ 0\\.009732263013061744\ \(0\)\
\-\ an\\:\\ 0\\.009529555357134917\ \(0\)\
\-\ up\\:\\ 0\\.009265512705863803\ \(0\)\
\-\ common\\:\\ 0\\.009017206499824182\ \(0\)\
\-\ in\\:\\ 0\\.00849591189798901\ \(0\)\
\-\ increased\\:\\ 0\\.008429374120159901\ \(0\)\
\-\ imaging\\:\\ 0\\.008072878324417752\ \(0\)\
\-\ case\\:\\ 0\\.007538324326077705\ \(0\)\
\-\ but\\:\\ 0\\.007348803633199748\ \(0\)\
\-\ female\\:\\ 0\\.007083710771967071\ \(0\)\
\-\ also\\:\\ 0\\.006792820942218352\ \(0\)\
\-\ that\\:\\ 0\\.005951535195801706\ \(0\)\
\-\ on\\:\\ 0\\.005837830744882484\ \(0\)\
\-\ disease\\:\\ 0\\.0056320062145794525\ \(0\)\
\-\ normal\\:\\ 0\\.005401663123383472\ \(0\)\
\-\ be\\:\\ 0\\.0053135351747739075\ \(0\)\
\-\ ct\\:\\ 0\\.004819772795935657\ \(0\)\
\-\ a\\:\\ 0\\.004797578247805661\ \(0\)\
\-\ \\:\\:\\ 0\\.004557559741897843\ \(0\)\
\-\ is\\:\\ 0\\.004534603051489723\ \(0\)\
\-\ with\\:\\ 0\\.004246119293584708\ \(0\)\
\-\ of\\:\\ 0\\.0042279605128302256\ \(0\)\
\-\ this\\:\\ 0\\.003875553279492472\ \(0\)\
\-\ and\\:\\ 0\\.002177528295147804\ \(0\)\
\-\ \\.\\:\\ 0\\.0018608627792963774\ \(0\)\
\-\ to\\:\\ 0\\.00172204882436688\ \(0\)\
\-\ the\\:\\ 0\\.0005574567931597815\ \(0\)\
